Please ensure Javascript is enabled for purposes of website accessibility

This Could Be Johnson & Johnson’s Future

By Shruti Basavaraj Ahluwalia - Jul 6, 2015 at 2:23PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

As competition heats up for Johnson & Johnson's current blockbuster drugs like Zytiga and Remicade, we have to look into the pipeline to see what the future could hold.

There are two words that are critical to every pharmaceutical company investor.

No, not "blockbuster drug" -- high expectations for those are usually pretty well baked into stock prices by the time sales hit the earnings reports.

Not "patent expiration" either, although expiring or changing patents can have a big impact on a pharmaceutical company.

I'm talking about "pipeline promise," which describes what products are currently being developed, what stage those products are in, and the amount of market share that they might garner. And for those of us who don't have biomedical degrees, there are a variety of resources (including some fantastic ones from Foolish contributors!) that can help clarify the different stages of approval.

As competition heats up for key drugs, it becomes even more important for investors to evaluate a company's next generation drugs' future potential. Investors in a company like Johnson & Johnson (JNJ -0.48%), which is seeing increased competition for blockbuster drugs like Zytiga and Remicade, will have to look into its pipeline to see what the future could hold.

Big promise for big results
J&J has gone on record saying it "plans to file more than 10 new products by 2019, each with potential to exceed $1 billion in revenue." This is in addition to 40 line extensions, which expand pharmaceutical products by gaining approval for new indications or new formulations of existing products, in the same time frame.

But does this promise ring true? J&J is looking to daratumumab, a potential treatment for multiple myeloma, to help fulfill this commitment. The American Cancer Society estimates that there will be 26,850 new cases of multiple myeloma in 2015. This particular type of blood cancer has a poor prognosis and limited treatment options for patients who relapse, making daratumumab a key drug for J&J. 

Daratumumab is in phase 3 development in both the U.S. and the EU and has received a Breakthrough Therapy Designation from the FDA, which will help expedite its approval process. With expectations to submit applications on a rolling basis, the hope is that sales could begin as soon as 2016 and hit the $1 billion mark before 2019.

Another key pipeline drug is sirukumab, which is being co-developed with GlaxoSmithKline as a treatment for rheumatoid arthritis. Sirukumab is also in phase 3 in both the U.S. and EU. According to a recent study by Research and Markets, over 8.5 million people globally may be diagnosed with rheumatoid arthritis by 2023. Sirukumab could be a key option for patients who have failed other treatments. Although facing competition from other developing drugs like Eli Lilly's baricitinib and Sanofi and Regeneron's sarilumab, the size of this market worldwide could support multiple players.

A third intriguing pipeline candidate is the psoriasis treatment guselkumab. With concerns about J&J's Stelara facing stiff competition from other companies, guselkumab has the potential to help J&J remain competitive in the psoriasis market against Novartis' recently-approved Cosentyx. However, Cosentyx has the advantage in being the first to gain approval in the class of psoriasis drugs known as IL-17 inhibitors, so investors should keep a close eye to see whether guselkumab can compete effectively.

These three promising drugs will be key to J&J's future as a top-tier pharmaceutical company, particularly as key patents expire. More conservative investors might want to take a wait and see approach to J&J until we know for sure that these new drugs will bring in enough revenue to outweigh the loss of revenue from generic competition on older drugs. However, as a shareholder, I think J&J's future looks bright. 

Shruti Basavaraj Ahluwalia owns shares of Johnson & Johnson. The Motley Fool recommends GlaxoSmithKline and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
$166.77 (-0.48%) $0.81
Sanofi Stock Quote
$41.19 (-2.35%) $0.99
Novartis AG Stock Quote
Novartis AG
$84.92 (-0.35%) $0.30
Regeneron Pharmaceuticals, Inc. Stock Quote
Regeneron Pharmaceuticals, Inc.
$624.83 (-1.81%) $-11.51
GSK Stock Quote
$34.25 (-0.17%) $0.06
GSK Stock Quote
$1,402.00 (0.20%) $2.85

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.